InvestorsHub Logo
Post# of 252816
Next 10
Followers 10
Posts 1097
Boards Moderated 0
Alias Born 08/23/2004

Re: gofishmarko post# 46950

Saturday, 05/19/2007 10:19:33 AM

Saturday, May 19, 2007 10:19:33 AM

Post# of 252816
<<The odds of Provenge providing a survival benefit , based on available data , are much better than the odds for Gemzar in ovarian , which are near zero , based on data on the label.
>>

and this is why you can't understand the FDA's decision. Because you "believe" Provenge works; even though the vaccine does not stimulate an immune response to an antigen in prostate cancer cells and even though the survival data is shaky -- yes, the oS number was significant for that trial. Unfortunately, the trial was too small.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.